ClinicalTrials.gg
RecruitingNCT06486454Updated Nov 6, 2026

Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)

An observational study in Liver Neoplasms, Primary Liver Cancer and Secondary Liver Cancer, sponsored by HistoSonics, Inc.. Recruiting at 35 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by HistoSonics, Inc. · Observational

How we know · 2 judgments

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.
Updated Nov 6, 20262 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
5,000
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 566 studies in Liver Neoplasms with a site in United States — 82 open to participants now, 121 under way, 6 of them phase 3. Liver Neoplasms · United States.

Planned enrollment
11th of 111
5,000 · median 143
Started
2024
with 20 others
Observational
111 of 566
25 open now
Primary completion
2034-11
later than 112 of 118 live
Registered
515th of 566
by date

Among the 566 studies in Liver Neoplasms with a site in United States, this one is the 11th largest by planned enrollment of the 111 observational ones that give a count, is one of 21 that started in 2024, is one of 111 observational ones, reaches primary completion later than 112 of the 118 other live ones, and was the 515th registered.

Liver Neoplasms

1,348 studies on the registry are indexed under Liver Neoplasms; 337 are open to participants now.

Browse Liver Neoplasms studies →

Open to participants now

82 of the 566 studies in Liver Neoplasms with a site in United States are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 244 Liver Neoplasms studies recruiting now, 137 (56%) set no upper age limit and 70 (29%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 566 studies in Liver Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The goal of this observational study is to collect information on the use of the HistoSonics Edison System for the treatment of liver tumors. The main aim is to understand how different patient characteristics and procedural characteristics may affect histotripsy success at 36 hours post-histotripsy procedure. Sub-studies to the BOOMBOX: Master Study will investigate specific populations and/or clinical questions with more stringent enrollment criteria, standardized testing criteria, and/or follow-up schedule. Any participant enrolled in the BOOMBOX: Master Study that also qualifies for a sub-study may enroll in the sub-study in parallel; sub-studies will be described in separate sub-study protocols. The BOOMBOX: Master Study will collect information about participants before, during, and after the histotripsy treatment procedure. All participants will be followed per standard clinical follow-up based on each site's clinical practice for up to 5 years after the initial histotripsy procedure or until completion of their follow-up in a sub-study, whichever is longer.

Read the detailed description

BOOMBOX: Master Study is an observational, single arm, non-randomized, prospective master study. Following histotripsy treatment of liver tumor(s), subjects will undergo imaging ≤36 hours post-histotripsy treatment procedure to determine histotripsy success. Subjects will then be followed per standard clinical follow-up as determined at each site with regular review of adverse event data for up to 5 years or until completion of their follow-up in a sub-study, whichever is longer.

As an observational study, the master protocol does not direct the use of the HistoSonics Edison System towards any specific clinical intent or any specific disease state. Rather, it will uniformly enroll patients and capture real-world standard-of-care data on the usage of the HistoSonics Edison System as implemented by the treating physician on all subjects treated with histotripsy that meet the study criteria and agree to participate in the study. Sub-studies to the master protocol will investigate specific populations and/or clinical questions with more stringent enrollment criteria, standardized testing criteria, and/or follow-up schedule. Any subject enrolled in the master study who also qualifies for a sub-study may enroll in the sub-study in parallel to the master study.

03

Conditions studied

  • Liver Neoplasms
  • Primary Liver Cancer
  • Secondary Liver Cancer
  • Tumor Liver
  • Benign Liver Tumor

Keywords

  • histotripsy
04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Subjects who are 22 years of age or older with a diagnosis of: primary (e.g., HCC, cholangiocarcinoma, angiosarcoma) or metastatic (from other primary cancers) liver cancer, or benign liver tumors (e.g., adenoma).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is ≥22 years of age
  2. Subject has signed the Ethics Committee (EC), or Institutional Review Board (IRB) approved study Form (ICF) prior to any study related tests/procedures and is willing to comply with study procedures and required follow-up assessments
  3. Subject's liver tumor(s) can be partially or completely treated with histotripsy

Exclusion criteria

Exclusion Criteria:

  1. Subject is pregnant or planning to become pregnant or nursing (lactating) during the study period
  2. Subject is enrolled in an interventional HistoSonics-sponsored trial
  3. Subject has a concurrent condition that, in the investigator's opinion, could jeopardize the safety of the subject or compliance with the protocol
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
5,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • HistoSonics Edison System

    Device: HistoSonics Edison System

Interventions

  • DeviceHistoSonics Edison System

    Histotripsy with the HistoSonics Edison System for the full or partial destruction of liver tumors

    Also known as: Histotripsy

06

What researchers measure

Primary outcomes

  1. Histotripsy Technical Success

    Histotripsy technical success, defined as completion of histotripsy on the target tumor(s) according to the histotripsy treatment plan, assessed by the treating physician on CT or MR imaging at ≤36 hours post-histotripsy treatment procedure. The histotripsy treatment plan will include identification of the intended complete or partial treatment of the tumor(s). The histotripsy treatment zone must provide target tumor coverage greater than or equal to the degree of treatment intended.

    Time frame: ≤36 hours post-histotripsy treatment procedure

07

Study locations

32 of 35 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Nov 2034, 121 months after the start.

Of 160 observational studies under Liver Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 172. This study's planned 121 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2024
First posted
Jul 3, 2024
StartActual
Oct 14, 2024
Primary completionEst.
Nov 2034
CompletionEst.
Nov 2039
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 United States)
  • University of South Alabama · Mobile, United States
  • Northwell Health · Manhasset, United States
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    2 sites added
    Show 2 added (2 United States)
    • University of South Alabama · Mobile, United States
    • Northwell Health · Manhasset, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06486454
Lead sponsor
HistoSonics, Inc.
Responsible party
Sponsor
First posted
Jul 3, 2024
Start date
Oct 14, 2024
Primary completion
Nov 2034 (estimated)
Completion
Nov 2039 (estimated)
Last update
Nov 6, 2026

Study contacts

Michelle Biedenfeld
Contact
Michelle.Biedenfeld@histosonics.com
605-354-1448
Christine Frederiksen
Contact
christine.frederiksen@histosonics.com
307-262-7118

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion